- Home
- Editorial
- News
- Practice Guidelines
- Anesthesiology Guidelines
- Cancer Guidelines
- Cardiac Sciences Guidelines
- Critical Care Guidelines
- Dentistry Guidelines
- Dermatology Guidelines
- Diabetes and Endo Guidelines
- Diagnostics Guidelines
- ENT Guidelines
- Featured Practice Guidelines
- Gastroenterology Guidelines
- Geriatrics Guidelines
- Medicine Guidelines
- Nephrology Guidelines
- Neurosciences Guidelines
- Obs and Gynae Guidelines
- Ophthalmology Guidelines
- Orthopaedics Guidelines
- Paediatrics Guidelines
- Psychiatry Guidelines
- Pulmonology Guidelines
- Radiology Guidelines
- Surgery Guidelines
- Urology Guidelines
Gut bacteria therapy may help reduce weight gain
New York : The researchers found that incorporating the engineered bacteria into the guts of mice both kept them from gaining weight and protected them against some of the negative health effects of obesity.
"Some day in the future, it might be possible to treat the worst effects of obesity simply by administering these bacteria," said lead researcher Sean Davies, Associate Professor of Pharmacology at Vanderbilt University in Nashville, Tennessee, US.
"Because of the sustainability of gut bacteria, this treatment would not need to be every day," Davies noted.
To find out whether obesity-related diseases might be treated or even prevented by altering the gut microbiota, they engineered gut bacteria that produce a small lipid that helps suppress appetite and reduce inflammation.
People who are obese typically produce less of this lipid, which is made by the small intestine.
"Our new studies focused on mice highly prone to develop atherosclerosis and fatty liver disease, and we showed that the engineered bacteria were beneficial not only in inhibiting obesity, but also in protecting against fatty liver disease and somewhat against atherosclerosis (hardening of the arteries)," Davies said.
They also gave the engineered bacteria to mice with increased susceptibility to atherosclerosis and fatty liver disease.
The findings were presented at the American Physiological Society's Inflammation, Immunity and Cardiovascular Disease conference in Westminster, Colorado.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd